EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseVergleichsstudieÜbersichtsarbeit

Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis

Kadriye Bir Yucel, Yusuf Ilhan, Elvina Almuradova, Murat Bardakci, Cigdem Dinckal, Yakup Ergun

Cancer Treatment Reviews · 2026-02 · 143 · 103074

DOI: 10.1016/j.ctrv.2025.103074 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Treatment Reviews, 2026-02. Verfasst von Kadriye Bir Yucel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ankara Etlik City Hospital, Department of Medical Oncology, Ankara, Türkiye. Electronic address: kadriyebiryucel@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: European Society for Medical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) overexpression defines a distinct breast cancer (BC) subtype that is highly sensitive to anti-HER2 therapy. However, the predictive and prognostic value of varying HER2 expression levels-specifically immunohistochemistry (IHC) 3 + versus IHC 2+/in situ hybridization (ISH)-positive-tumors remains uncertain. This systematic review and meta-analysis compared pathological complete response (pCR) between these subgroups in early-stage HER2-positive BC treated with anti-HER2-based neoadjuvant chemotherapy (NACT). METHODS: Following PRISMA guidelines (PROSPERO: CRD420251066320), PubMed, EMBASE, Cochrane Library, and ClinicalTrials databases were searched up to June 2025. Eligible studies compared HER2 (3 + ) and HER2 (2 + )/ISH + early-stage BC receiving anti-HER2-based NACT. Data extraction was performed independently by two reviewers. Pooled odds ratios (ORs) and hazard ratios (HRs) were calculated using fixed- or random-effects models according to heterogeneity. RESULTS: Thirteen retrospective studies involving 7,206 patients were included. Among 6,081 HER2-positive cases, 76 % were HER2 (3 + ) and 24 % were HER2 (2 + )/ISH + . The pooled pCR rate was significantly higher in HER2 (3 + ) tumors than in HER2 (2 + )/ISH + tumors (55.1 % vs. 21.6 %; OR = 5.38, 95 % CI: 3.72-7.80; p < 0.00001). The difference persisted in dual-targeted regimens (66.0 % vs. 32.9 %; OR = 4.31, 95 % CI: 2.70-6.88; p < 0.00001). No significant difference was observed in 3-year invasive disease-free survival (HR = 0.71, 95 % CI: 0.32-1.57; p = 0.40). CONCLUSION: HER2 IHC 3 + tumors are substantially more likely to achieve pCR following anti-HER2-based NACT than HER2 (2 + )/ISH + tumors, indicating that HER2 expression intensity has predictive relevance. Quantitative HER2 assessment should be integrated into therapeutic planning and trial stratification to optimize outcomes in early-stage HER2-positive BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansPathologic Complete ResponseFemaleImmunohistochemistryNeoadjuvant TherapyIn Situ HybridizationNeoplasm StagingPrognosis

Stichwörter der Autor:innen

Breast cancerHER-positiveNeoadjuvant treatmentPathological complete response

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Ankara Etlik City Hospital, Department of Medical Oncology, Ankara, Türkiye. Electronic address: kadriyebiryucel@gmail.com.
  • Antalya City Hospital, Department of Medical Oncology, Antalya, Turkiye. Electronic address: dryusufilhan@gmail.com.
  • Can Hospital, Department of Medical Oncology, Izmir, Türkiye. Electronic address: almuradovaelvina@gmail.com.
  • Gazi Yasargil Traning and Research Hospital, Department of Medical Oncology, Diyarbakir, Türkiye. Electronic address: dr.muratbardakci@hotmail.com.
  • Harakani State Hospital, Department of Medical Oncology, Kars, Türkiye. Electronic address: drcigdemdinckal@gmail.com.
  • Bower Hospital, Department of Medical Oncology, Diyabakir, Türkiye. Electronic address: dr.yakupergun@gmail.com.

Förderung

  • European Society for Medical Oncology

Zitieren

APA

Yucel, K. B., Ilhan, Y., Almuradova, E., Bardakci, M., Dinckal, C., & Ergun, Y. (2026). Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis. Cancer Treatment Reviews, 143, 103074. https://doi.org/10.1016/j.ctrv.2025.103074

Vancouver

Yucel KB, Ilhan Y, Almuradova E, Bardakci M, Dinckal C, Ergun Y. Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis. Cancer Treatment Reviews. 2026;143:103074. doi:10.1016/j.ctrv.2025.103074

BibTeX
@article{Yucel2026,
  author = {Yucel, Kadriye Bir and Ilhan, Yusuf and Almuradova, Elvina and Bardakci, Murat and Dinckal, Cigdem and Ergun, Yakup},
  title = {Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis},
  journal = {Cancer Treatment Reviews},
  year = {2026},
  volume = {143},
  pages = {103074},
  doi = {10.1016/j.ctrv.2025.103074}
}
Kostenlos starten →